The landscape for biotech entrepreneurship and small business funding has shifted in the last few decades. At the NIH SBIR/STTR, spending limits increased to more than $980M in 2017, eligibility was revised to include small businesses majority owned by VC operating companies and additional non-financial advisory services are now offered to small businesses to help them advance their product development programs. Some VC firms and large pharmaceutical companies also expanded their activities to include incubation and mentoring of nascent startups.
Stakeholders will learn how collaborating with, and licensing from, NIH innovators and assets helps to build pipelines and overcome development challenges in a non-dilutive manner. This panel will illustrate how strategic initiatives at the NIH focus on connecting small business awardees with third party investors and partners. Panelists, including both funding partners and small business awardees, will discuss current initiatives available to companies of any size, anywhere in the world to advance medical solutions.
Session ID: 1020173